GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Febuxostat (ULORIC, adults)

Local official-label summaryBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Uloric

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Before use: Febuxostat (ULORIC, adults)

Fresh official labeling adds the renal cap together with the cardiovascular and treatment-selection restrictions; the earlier RX source remains separately dated.

Before applying: Check the allopurinol treatment history, cardiovascular risk, renal range and interacting medicines before applying the renal limit.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Febuxostat - ULORIC official renal restrictions

Product / population
Adults with gout when maximally titrated allopurinol is inadequate, not tolerated or not advisable.
Renal measure
Creatinine clearance, mL/min.

Renal guidance and important limits

Limits that apply to these rows

The cardiovascular-death boxed warning remains relevant; no-adjustment wording is not cardiovascular clearance.

Concomitant azathioprine or mercaptopurine is contraindicated. Do not apply this gout regimen to asymptomatic or secondary hyperuricemia.

ULORIC renal dose limit
CrCl (mL/min)Source-specific instruction
30-89No renal dose adjustment
15-29Limit to 40 mg once daily
ESRD on dialysisNot studied; no regimen established by the selected source
Read the retained text before reformatting

ULORIC renal dose limit

CrCl (mL/min)Source-specific instruction
30-89No renal dose adjustment
15-29Limit to 40 mg once daily
ESRD on dialysisNot studied; no regimen established by the selected source

The cardiovascular-death boxed warning remains relevant; no-adjustment wording is not cardiovascular clearance.

Concomitant azathioprine or mercaptopurine is contraindicated. Do not apply this gout regimen to asymptomatic or secondary hyperuricemia.

Source revision: 4/2023 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54de10ef-fe5f-4930-b91d-6bbb04c664bd

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Febuxostat - ULORIC official renal restrictions

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the allopurinol treatment history, cardiovascular risk, renal range and interacting medicines before applying the renal limit.

Adults with gout when maximally titrated allopurinol is inadequate, not tolerated or not advisable.

Renal method: Creatinine clearance, mL/min.
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Uloric

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult oral febuxostat for qualifying gout; not asymptomatic hyperuricemia.

Renal method: CLcr in mL/min
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Before use: Febuxostat (ULORIC, adults)

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Before use: Febuxostat (ULORIC, adults)

Fresh official labeling adds the renal cap together with the cardiovascular and treatment-selection restrictions; the earlier RX source remains separately dated.

How to use this: Check the allopurinol treatment history, cardiovascular risk, renal range and interacting medicines before applying the renal limit.

Febuxostat - ULORIC official renal restrictions

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeFebuxostat - ULORIC official renal restrictionsGlobalRPh RX List - Uloric
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/uloric-drug/

Exact product and population

Adult oral febuxostat for qualifying gout; not asymptomatic hyperuricemia.

RDM36-SCOPE-febuxostat-uloric · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Febuxostat - ULORIC official renal restrictions

Open original reference

Open / share this exact local source

DailyMed / NLM exact product labeling · Adults with gout when maximally titrated allopurinol is inadequate, not tolerated or not advisable.

Renal method: Creatinine clearance, mL/min.
Source date: 4/2023
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the allopurinol treatment history, cardiovascular risk, renal range and interacting medicines before applying the renal limit.

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

The cardiovascular-death boxed warning remains relevant; no-adjustment wording is not cardiovascular clearance.

Concomitant azathioprine or mercaptopurine is contraindicated. Do not apply this gout regimen to asymptomatic or secondary hyperuricemia.

ULORIC renal dose limit
CrCl (mL/min)Source-specific instruction
30-89No renal dose adjustment
15-29Limit to 40 mg once daily
ESRD on dialysisNot studied; no regimen established by the selected source
Read the retained text before reformatting

ULORIC renal dose limit

CrCl (mL/min)Source-specific instruction
30-89No renal dose adjustment
15-29Limit to 40 mg once daily
ESRD on dialysisNot studied; no regimen established by the selected source

The cardiovascular-death boxed warning remains relevant; no-adjustment wording is not cardiovascular clearance.

Concomitant azathioprine or mercaptopurine is contraindicated. Do not apply this gout regimen to asymptomatic or secondary hyperuricemia.

RDM64-official-febuxostat-uloric-67fd73deaf-C1 · Source locator: Boxed warning; sections 1, 2.2, 4, 8.6 and 12.3.

Source-specific limits

The cardiovascular-death boxed warning remains relevant; no-adjustment wording is not cardiovascular clearance.

Concomitant azathioprine or mercaptopurine is contraindicated. Do not apply this gout regimen to asymptomatic or secondary hyperuricemia.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54de10ef-fe5f-4930-b91d-6bbb04c664bd
Retrieved
2026-09-10
Exact label title
Febuxostat - ULORIC official renal restrictions
DailyMed Set ID
54de10ef-fe5f-4930-b91d-6bbb04c664bd
Label revision
4/2023
Renal-function method
Creatinine clearance, mL/min.
Source date/version
4/2023
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
321ec05791fbe523d3c054a4270537b0257533bdb2000d253d32910a86d54465
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Uloric

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult oral febuxostat for qualifying gout; not asymptomatic hyperuricemia.

Renal method: CLcr in mL/min
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

CLcr 30-89 mL/min does not require renal dose modification. For CLcr 15-29 mL/min, limit ULORIC to 40 mg once daily. Dialysis patients were not studied. The usual adult starting dose is 40 mg daily; the severe-impairment limit prevents routine escalation to 80 mg. The source restricts its gout indication to patients with inadequate response to maximally titrated allopurinol, intolerance, or a reason allopurinol is not advisable, and warns about increased cardiovascular-death risk. It is not recommended for asymptomatic hyperuricemia.

RDM36-rxlist-febuxostat-uloric-e17de32190-C1 · Source locator: Dosage; use in specific populations: renal impairment; PK; boxed warning and indication.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/uloric-drug/
Retrieved
2026-09-07
Renal-function method
CLcr in mL/min
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
3d023d9f33fe7c2eae1392d404dbabab4ad722035c89f0dcadb0603e2abe34f1

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/uloric-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
4a7c3905a86df4f1e3bc30002c732e36b65184c6556ad7f63c05bf594d9a9c48
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report